Metagenomi (NASDAQ:MGX) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Metagenomi (NASDAQ:MGX) from a sell rating to a strong sell rating in a research note released on Saturday.

A number of other research analysts have also weighed in on MGX. Wells Fargo & Company dropped their price target on shares of Metagenomi from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings upgraded shares of Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Metagenomi Price Performance

MGX opened at $1.31 on Friday. The company’s 50-day moving average is $1.43 and its 200 day moving average is $1.63. Metagenomi has a fifty-two week low of $1.25 and a fifty-two week high of $3.95. The firm has a market capitalization of $49.32 million, a P/E ratio of -0.57 and a beta of 0.63.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Metagenomi had a negative net margin of 384.61% and a negative return on equity of 51.23%. The firm had revenue of $1.25 million for the quarter, compared to the consensus estimate of $5.90 million. On average, equities research analysts expect that Metagenomi will post -2.1 earnings per share for the current year.

Institutional Trading of Metagenomi

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its holdings in Metagenomi by 25.4% during the first quarter. Renaissance Technologies LLC now owns 787,900 shares of the company’s stock worth $1,056,000 after buying an additional 159,500 shares during the last quarter. Peapod Lane Capital LLC increased its stake in shares of Metagenomi by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 513,815 shares of the company’s stock worth $1,218,000 after purchasing an additional 5,706 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Metagenomi by 341.6% in the fourth quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock worth $703,000 after purchasing an additional 335,604 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in shares of Metagenomi by 102.1% in the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Metagenomi by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 305,908 shares of the company’s stock worth $496,000 after purchasing an additional 14,018 shares in the last quarter.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.